MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on the discovery, development and commercialization of novel therapies genes, biologics and vaccines, announced that Dr. Shankar Musunuri, CEO and co-founder of Ocugen, will present virtually at HC Wainwright 2n/aAnnual Virtual Ophthalmology Conference August 17.
A video webcast of the presentation will be available on demand beginning at 7 a.m. ET on August 17, 2022 for those registered for the event and will be available on the events Ocugen page investor website. The webcast replay will be archived for 90 days after the event.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel gene and cell therapies and vaccines that improve health and offer hope to patients worldwide. We impact patients’ lives through courageous innovation, forging new scientific avenues that harness our unique intellectual and human capital. Our breakthrough gene-modifying therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing infectious disease research to support public health and orthopedic disease to address unmet medical needs. Find out more about www.ocugen.com and follow us on Twitter and LinkedIn.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts”, “believes”, “potential”, “proposed”, “continues”, “estimates”, “anticipates”, “expects”, “plans”. , “intends,” “may,” “could,” “could,” “will,” “should,” or other words that convey uncertainty of future events or results to identify these forward-looking statements. These statements are subject to numerous important factors, risks and uncertainties that could cause actual events or results to differ materially from our current expectations.These and other risks and uncertainties are described in more detail in our filings. with the Securities and Exchange Commission (SEC), including the risk factors described in the section titled “Risk Factors” in our quarterly and annual reports that we file with the SEC. Any forward-looking statements we make in this press release are only valid as of the date of this press release. Except as required by law, we undertake no obligation to update any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date of this Press release.
Contact:
Tiffany Hamilton
Communications Manager
Copyright 2022 GlobeNewswire, Inc.
